|
[1]
|
Kommalapati, A., Tella, S.H., Durkin, M., Go, R.S. and Goyal, G. (2018) Histiocytic Sarcoma: A Population-Based Analysis of Incidence, Demographic Disparities, and Long-Term Outcomes. Blood, 131, 265-268. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Sabattini, E., Bacci, F., Sagramoso, C., et al. (2010) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues in 2008: An Overview. Pathologica, 102, 83-87.
|
|
[3]
|
Kobayashi, S., Kimura, F., Hama, Y., Ogura, K., Torikai, H., Kobayashi, A., et al. (2008) Histiocytic Sarcoma of the Spleen: Case Report of Asymptomatic Onset of Thrombocytopenia and Complex Imaging Features. International Journal of Hematology, 87, 83-87. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Egan, C., Nicolae, A., Lack, J., Chung, H., Skarshaug, S., Pham, T.A., et al. (2019) Genomic Profiling of Primary Histiocytic Sarcoma Reveals Two Molecular Subgroups. Haematologica, 105, 951-960. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Peng, Y.J. and He, Y.Q. (2024) Histiocytic Sarcoma of the Spleen without Thrombocytopenia. Revista Española de Enfermedades Digestivas, 116, 703-704. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Chen, F., Jin, H.F., Fan, Y.H., Cai, L.J., Zhang, Z.Y. and Lv, B. (2015) Case Report of Primary Splenic Angiosarcoma with Hepatic Metastases. World Journal of Gastroenterology, 21, 11199-11204. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Gan, M., He, X. and Zheng, X. (2024) FDG PET/CT Imaging of Liver and Spleen Histiocytic Sarcoma. Clinical Nuclear Medicine, 49, 272-273. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Valizadeh, P., Jannatdoust, P., Tahamtan, M., Soleimani Dorcheh, S., Khalaj, F., Ghorani, H., et al. (2024) Differentiating Malignant from Benign Splenic Lesions: A Meta-Analysis and Pictorial Review of Imaging Features. Abdominal Radiology, 49, 2833-2857. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Harwood, M., Craig, F.E. and Yang, M. (2021) Rare Multisystem Histiocytic Sarcoma on 18f-FDG PET/CT. Journal of Nuclear Medicine Technology, 49, 358-359. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Hung, Y.P. and Qian, X. (2020) Histiocytic Sarcoma. Archives of Pathology & Laboratory Medicine, 144, 650-654. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Kramer, P., Prins, M.E.F., Kapsenberg, J.G., Bornkamm, G.W., Bijnen, A.B., Rohol, P.J.M., et al. (1985) Persistent Epstein-Barr Virus Infection and a Histiocytic Sarcoma in a Renal Transplant Recipient. Cancer, 55, 503-509. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Durham, B.H., Diamond, E.L. and Abdel-Wahab, O. (2016) Histiocytic Neoplasms in the Era of Personalized Genomic Medicine. Current Opinion in Hematology, 23, 416-425. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Koh, K.N., Yoon, S.H., Kang, S.H., Kim, H. and Im, H.J. (2024) Advancements in the Understanding and Management of Histiocytic Neoplasms. Blood Research, 59, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Ozkaya, N., Dogan, A. and Abdel-Wahab, O. (2017) Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. Hematology/Oncology Clinics of North America, 31, 705-719. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Cohen Aubart, F., Emile, J., Maksud, P., Galanaud, D., Cluzel, P., Benameur, N., et al. (2018) Efficacy of the MEK Inhibitor Cobimetinib for Wild‐Type BRAF Erdheim‐Chester Disease. British Journal of Haematology, 180, 150-153. [Google Scholar] [CrossRef] [PubMed]
|